{
  "ticker": "JNJ",
  "target_date": "2025-02-18",
  "actual_date": "2025-02-18",
  "collected_at": "2025-12-08T11:25:07.084117",
  "price": {
    "open": 150.76,
    "high": 152.04,
    "low": 149.88,
    "close": 151.59034729003906,
    "volume": 9670700,
    "change_1d_pct": 0.05,
    "change_7d_pct": 1.77,
    "change_30d_pct": 8.48
  },
  "technicals": {
    "rsi_14": 69.59,
    "sma_20": 147.89,
    "sma_50": 143.99,
    "macd": 2.326,
    "macd_signal": 2.0,
    "macd_histogram": 0.326,
    "bb_upper": 154.57,
    "bb_lower": 141.2,
    "price_vs_sma20_pct": 2.5,
    "price_vs_sma50_pct": 5.28,
    "volume_ratio": 1.04
  },
  "fundamentals": {
    "market_cap": 488750088192,
    "pe_ratio": 19.5811,
    "forward_pe": 19.137754,
    "price_to_book": 6.157168,
    "price_to_sales": 5.303911,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.38,
    "pct_from_52w_low": 44.2
  },
  "macro": {
    "spy": {
      "price": 606.18,
      "change_1d_pct": 0.29,
      "change_7d_pct": 1.78
    },
    "vix": {
      "level": 15.35,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.54
    },
    "dollar_index": {
      "level": 107.05
    },
    "gold": {
      "price": 2931.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan",
      "source": "DowJones",
      "datetime": 1739899320,
      "summary": "Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan",
      "url": "https://finnhub.io/api/news?id=552ba1815bc22ef4357a898953418872759b36ce72840a60da7486619725d271"
    },
    {
      "headline": "American Century Equity Income Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1739865600,
      "summary": "Growth stocks outpaced their value counterparts during the quarter, even as some investors sought lower-volatility positions. Read more here.",
      "url": "https://finnhub.io/api/news?id=24059a49384deda6cb03e2a6a8cc929779b10eefc7554041ca94201b12b89841"
    },
    {
      "headline": "Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon",
      "source": "SeekingAlpha",
      "datetime": 1739845553,
      "summary": "Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion in cash. Read more here.",
      "url": "https://finnhub.io/api/news?id=c1d6b14105926a08ff7e19ff286d926c37916f912b70debf4d6b1fa4ee9261f2"
    },
    {
      "headline": "Johnson & Johnson: Rich History Of Excellence Poised To Endure",
      "source": "SeekingAlpha",
      "datetime": 1739845013,
      "summary": "Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a Strong Buy rating for JNJ stock.",
      "url": "https://finnhub.io/api/news?id=2009007b3a8fa13fd665e3645d0dcb6a750e72709c6e6463f20513c66552b02c"
    },
    {
      "headline": "Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025",
      "source": "SeekingAlpha",
      "datetime": 1739800800,
      "summary": "Kenvue, spun off from J&J, offers long-term dividend potential with strong brands like Tylenol and Listerine. Click here to read an analysis of KVUE stock now.",
      "url": "https://finnhub.io/api/news?id=e6233d044b85795db6aca7a175e1ead5c56f9e8079c29712b0417b35a05cce45"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-02-18",
      "description": "xslF345X05/wk-form4_1739933175.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000062/xslF345X05/wk-form4_1739933175.xml"
    },
    {
      "form": "4",
      "date": "2025-02-18",
      "description": "xslF345X05/wk-form4_1739932395.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000060/xslF345X05/wk-form4_1739932395.xml"
    },
    {
      "form": "4",
      "date": "2025-02-18",
      "description": "xslF345X05/wk-form4_1739931408.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000058/xslF345X05/wk-form4_1739931408.xml"
    },
    {
      "form": "4",
      "date": "2025-02-18",
      "description": "xslF345X05/wk-form4_1739931179.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000056/xslF345X05/wk-form4_1739931179.xml"
    },
    {
      "form": "4",
      "date": "2025-02-18",
      "description": "xslF345X05/wk-form4_1739931099.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000054/xslF345X05/wk-form4_1739931099.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}